Health care regulation, the Food and Drug Administration (FDA), and access to medicine : Our experience with dupilumab for children - 17/02/20
Abbreviations used : FDA
El texto completo de este artículo está disponible en PDF.
Authors Wang and Zheng contributed equally to this work. |
|
Funding sources: None. |
|
Conflicts of interest: Dr Siegfried, possibly related: principal investigator clinical trial, consulting fees, and honorarium for Regeneron; consulting fees and honorarium for Sanofi Genzyme; consulting fees for UCB and AbbVie. Unrelated: consulting fees and honorarium for Verrica; consulting fees and Data Safety Monitoring Committees for LEO Pharma and Novan; consulting fees for Pfizer and Pierre Fabre; principal investigator, clinical trial for Janssen; and principal investigator for Lilly. Authors Wang, Zheng, Doerrer, Kurta, and Shelley have no conflicts of interest to declare. |
|
IRB approval status: The primary data used in this article are obtained from studies approved by the SLU IRB. |
|
Reprints not available from the authors. |
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?